Intertek opens bioanalysis plant in UK to support biosimilar growth
In May, Intertek opened a stability testing facility for small molecules and biologics in Royston, near Cambridge, UK, and today the contract services firm has announced its10,000 ft² bioanalytical and biopharmaceutical characterisation facility is now open for business in Manchester.
The site will offer drug companies bioanalysis, immunogenicity and characterisation services for monoclonal antibodies (mAbs), recombinant proteins and vaccines, and will operate as part of Intertek’s Centre of Excellence for Biologics.
“This investment is key to providing the level of resource required to meet the ever increasing demand for our expertise and experience,” said Chetan Parmar, Intertek’s Senior Vice President.
“Among the exciting projects now starting at this lab is testing of novel monoclonal antibody therapeutics, as well as antibody drug conjugates, which are highly complex yet offer great potential for a range of difficult-to-treat cancers.”
The company says it is seeing a growing demand for contract safety and efficacy services for biologics, as well as comparability and characterization testing services for mAbs, driven in part by the growth in biosimilar development.
The expansion was announced earlier this year, with a spokeswoman at the time telling this publication the lab mirrors the firm’s existing San Diego immunochemistry facility.
